MoonLake Immunotherapeutics (MLTX) Change in Accured Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 557.78% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $11.3 million, a 75.55% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, down 49.87% from the prior year.
• Change in Accured Expenses rose to $7.1 million in Q1 2026 per MLTX's latest filing, from -$6.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $12.9 million in Q3 2025 and bottomed at -$6.9 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $1.4 million (2023), against an average of $1.0 million.
• Across the five-year window, Change in Accured Expenses tumbled 18799.85% in 2022 and jumped 557.78% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $2.2 million in 2022, then grew by 28.06% to $2.9 million in 2023, then soared by 45.51% to $4.2 million in 2024, then plunged by 265.24% to -$6.9 million in 2025, then soared by 203.28% to $7.1 million in 2026.
• Per Business Quant, the three latest MLTX Change in Accured Expenses figures stand at $7.1 million (Q1 2026), -$6.9 million (Q4 2025), and $12.9 million (Q3 2025).